Press Releases
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2024) - First Hydrogen Corp. (TSXV: FHYD) (OTC Pink: FHYDF) (FSE: FIT) ("FIRST HYDROGEN" or the "Company") has completed three successful vehicle trials of the Company's hydrogen-fuel-cell-powered vehicle (FCEV) and now has started trials with a large multinational logistics company, whose partners use commercial vans for parcel deliveries. The trial commenced in London, UK with driver training and is expected to... (continue reading...)
Toronto, Ontario--(Newsfile Corp. - May 6, 2024) - IberAmerican Lithium Corp. (CBOE: IBER) (OTCQB: IBRLF) (FSE: W2C) ("IberAmerican" or the "Company") is pleased to announce the engagement of Ms. Hannah Badenach as the Senior Commodities Strategist for the Company.
Ms. Badenach is an experienced executive and company director with more than 20 years of experience in resources, supply chains, business development, commodity trading and marketing in global markets across... (continue reading...)
FUZHOU, China, May 6, 2024 /PRNewswire/ -- On April 29, 2024, SOUEAST Motor hosted the "Hi, SOUEAST" Global Investment Promotion Conference in Fuzhou, China, attracting hundreds of potential dealer partners from 23 countries.
Accelerating Global Expansion
"SOUEAST Motor aims to expand its presence to 80+ countries and regions, establishing 1,500 sales networks. We will invest in 10 KD factories and 3 manufacturing centers worldwide, aiming to achieve the strategic... (continue reading...)
Pursuant to the Market Abuse Regulation, article 19, Svitzer Group A/S, CVR-no. 44 79 14 47, (“Svitzer Group” or the “Company”) hereby notifies receipt of information of the following transactions made by members of the Board of Directors or Executive Management in Svitzer Group or their closely associated persons in Svitzer Group’s shares admitted to trading and official listing on Nasdaq Copenhagen A/S.
About Svitzer
Svitzer is a leading, global towage and... (continue reading...)
Restructuring of ownership in BW Energy Limited and exemption from the mandatory offer obligation
As previously disclosed, BW Group Limited ("BW Group") currently owns 191,903,110 shares in BW Energy Limited ("BW Energy"), corresponding to 74.38% of the issued and outstanding shares and voting rights in BW Energy.
As part of a corporate restructuring, BW Group is planning to separate BW Energy, as an oil & gas exploration business, from the maritime businesses held by... (continue reading...)
More Press Releases
View Older Stories-
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
-
OKX Ventures Announces Strategic Investment in EVG's Consumer-oriented Projects, Paving the Way for Novel Applications in SocialFi and GameFi
-
Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site
-
SINOX Group to Showcase the Latest Synlox e-Security System at Eurobike
-
Rimsys Launches Community-Driven Regulatory Intelligence
-
SINOX Group to Showcase Universal Laptop Locks Aligning with the AI Era at Computex Taipei 2024
-
Oma Savings Bank Plc: Manager´s Transactions – Closely associated person Tanja Mäkynen
-
Oma Savings Bank Plc: Manager´s Transactions – Jyrki Mäkynen
-
Share buy-back programme - week 18
-
Elbit Systems Schedules First Quarter 2024 Results Release For May 28, 2024
-
INRED and SES to Provide High-Throughput Connectivity Across Colombia’s Amazonas
-
LHV Pank to contest the fine decision by Estonian Financial Intelligence Unit
-
Renault Group: Communication related to the availability of the EMTN base prospectus 2024
-
Transactions in connection with share buyback programme
-
Preliminary data on early redemptions (prepayments)
-
Pierre Anjolras appointed Chief Operating Officer of VINCI
-
Marimekko celebrates the 60th anniversary of the Unikko print in Helsinki and Tokyo with public open-air fashion shows
-
QUADIENT: 2024 Financial calendar - Update
-
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
-
Exor Press Release - Periodic Report on the Buyback Program
-
Graphano Expands Zone 3 at LAB Graphite Project - Reports Remaining Program Results including 15.65 Metres Grading 7.91% Cg
-
KKR to Acquire Healthium from Apax Funds
-
TerraPay Continues to Attract Top Industry Talent, Names Hassan Chatila as Vice President and Global Head of Network
-
BrainChip and Frontgrade Gaisler to Augment Space-Grade Microprocessors with AI Capabilities
-
Xylem Unveils 'Reuse Brew'
-
SES to acquire Intelsat: Investor Relations Frequently Asked Questions
-
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
-
Health Canada Approves Nexstim NBS 6 System for Treatment of MDD
-
Aktsiaselts Infortar interim report for Q1 2024
-
Fingerprints and Infrafon collaborating on new smart badges for the European Medical and IoT market
-
Subsea7 share repurchases
-
M&P Receives a Specific License From the OFAC in Relation to Its Operations in Venezuela
-
Statement Concerning Eutelsat Group’s Ground Network
-
Ambri Agrees to Terms of Proposed Sale with Lender Consortium
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
Transaction in Own Shares
-
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
Start of Day Message
-
Market Update